Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Biotest AG - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Biotest AG - Product Pipeline Review - 2015', provides an overview of the Biotest AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Biotest AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Biotest AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Biotest AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Biotest AG's pipeline products Reason to Buy - Evaluate Biotest AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Biotest AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Biotest AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Biotest AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotest AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Biotest AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Biotest AG Snapshot 5 Biotest AG Overview 5 Key Information 5 Key Facts 5 Biotest AG - Research and Development Overview 6 Key Therapeutic Areas 6 Biotest AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Biotest AG - Pipeline Products Glance 12 Biotest AG - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Biotest AG - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Biotest AG - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Biotest AG - Drug Profiles 16 BT-094 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 hepatitis C virus immune globulin (human) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 BT-086 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 indatuximab ravtansine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 tregalizumab 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 fibrinogen concentrate (human) 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 BT-063 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Biotest AG - Pipeline Analysis 26 Biotest AG - Pipeline Products by Target 26 Biotest AG - Pipeline Products by Route of Administration 27 Biotest AG - Pipeline Products by Molecule Type 28 Biotest AG - Pipeline Products by Mechanism of Action 29 Biotest AG - Recent Pipeline Updates 30 Biotest AG - Dormant Projects 33 Biotest AG - Company Statement 34 Biotest AG - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Biotest AG - Key Manufacturing Facilities 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Biotest AG, Key Information 5 Biotest AG, Key Facts 5 Biotest AG - Pipeline by Indication, 2015 7 Biotest AG - Pipeline by Stage of Development, 2015 8 Biotest AG - Monotherapy Products in Pipeline, 2015 9 Biotest AG - Partnered Products in Pipeline, 2015 10 Biotest AG - Partnered Products/ Combination Treatment Modalities, 2015 11 Biotest AG - Phase III, 2015 12 Biotest AG - Phase II, 2015 13 Biotest AG - Phase I, 2015 14 Biotest AG - Preclinical, 2015 15 Biotest AG - Pipeline by Target, 2015 26 Biotest AG - Pipeline by Route of Administration, 2015 27 Biotest AG - Pipeline by Molecule Type, 2015 28 Biotest AG - Pipeline Products by Mechanism of Action, 2015 29 Biotest AG - Recent Pipeline Updates, 2015 30 Biotest AG - Dormant Developmental Projects,2015 33 Biotest AG, Subsidiaries 36 Biotest AG, Key Manufacturing Facilities 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.